18:22 , Jul 26, 2018 |  BC Innovations  |  Translation in Brief

A plasticity problem

New research from the University of Bordeaux suggests the synaptic pathology underlying Alzheimer’s disease is driven by aberrant activation of CAMK2 by β-amyloid oligomers. The findings may point to the missing link in how β-amyloid...
15:22 , May 4, 2018 |  BC Week In Review  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...
20:40 , Apr 27, 2018 |  BC Extra  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...
07:00 , Jun 25, 2009 |  BC Innovations  |  Cover Story

Low-Rhes approach to Huntington's

A central mystery of Huntington's disease has been why the mutant form of the huntingtin protein responsible for the condition is found throughout the body but only causes pathology in the brain's corpus striatum. Researchers...
08:00 , Nov 13, 2008 |  BC Innovations  |  Targets & Mechanisms

PLAyground in Alzheimer's

Lev Osherovich, Senior Writer  A survey of brain lipids revealing abnormal patterns in mice with Alzheimer's disease haspointed researchers from the Gladstone Institute of Neurological Disease and Harvard Medical School to a potentiallynew therapeutic target...
08:00 , Oct 27, 1997 |  BC Week In Review  |  Company News

CoCensys, Warner-Lambert deal

The partners extended for two years their 1995 collaboration to discover sub-type specific NMDA receptor antagonists that block glutamate neurotransmitter activity, and will include the discovery of compounds that modulate activity of AMPA glutamate receptors....
07:00 , Sep 22, 1997 |  BioCentury  |  Product Development

Antagonizing NMDA

When one compound in a chemical class has problems, it's no big deal. When two do, eyebrows begin to rise. When three do, it may be time to rethink the target. Further complicating the issue...